Pleiotropic effects of statins and their clinical significance.

[1]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[2]  H. Katus,et al.  Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. , 2000, Circulation.

[3]  B. Ansell.  Cholesterol, stroke risk, and stroke prevention , 2000, Current atherosclerosis reports.

[4]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[5]  R. Laaksonen,et al.  Low-density lipoprotein-independent effects of statins. , 1999, Current opinion in lipidology.

[6]  A. Dart,et al.  Lipids and the endothelium. , 1999, Cardiovascular research.

[7]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[8]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[9]  J. Larosa.  Women, dyslipoproteinemia, and estrogens. , 1998, Endocrinology and metabolism clinics of North America.

[10]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[11]  A. Palomäki,et al.  Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. , 1998, Journal of lipid research.

[12]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[13]  J. Davignon.  Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects. , 1998, The American journal of cardiology.

[14]  P. Libby,et al.  Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.

[15]  F. Bernini,et al.  Direct vascular effects of HMG-CoA reductase inhibitors. , 1997, Atherosclerosis.

[16]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R. Laaksonen,et al.  The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. , 1996, The American journal of cardiology.

[18]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[19]  F. Bernini,et al.  Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. , 1993, Atherosclerosis.

[20]  P. Lesnik,et al.  Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  A. Faggiotto,et al.  Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins? , 2000, Current atherosclerosis reports.

[22]  P. Sandset,et al.  Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.